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March 9, 2010:1051–4hosen for 2 reasons. First, recurrence of AF at 1 year is a common
nd clinically relevant end point. Second, recurrent AF data (as
pposed to time-to-recurrence) were available for all trials in our
eta-analysis except the ATHENA (A Trial With Dronedarone to
revent Hospitalization or Death in Patients With Atrial Fibrilla-
ion), which did not report rhythm status (4).
The numerators and denominators for the maintenance of sinus
hythm analysis reflect an intention-to-treat approach based upon
reatment allocation at randomization—acknowledging differences in
xperimental design across the incorporated trials. Patients in
AFNE (Dronedarone Atrial FibrillatioN study after Electrical
ardioversion) (5) were reported according to assignment at random-
zation. Cardioversion was performed at 5 to 7 days in a subgroup, and
he on-treatment analysis conducted in DAFNE only included these
atients, as noted by Dr. Lewalter. Alternatively, GEFACA (Grupo
e Estudio de Fibrilacio´n Auricular Con Amiodarona) (6) had a
uch longer 4-week run-in period in which patients who remained in
F had to agree to cardioversion, and therefore we used a denomi-
ator at the end of the run-in period. With respect to SAFE-T
Sotalol Amiodarone Atrial Fibrillation Efficacy Trial) (7), 14 patients
3%) were withdrawn from the study; however, their inclusion does
ot meaningfully change the odds ratio (OR) for the treatment effect.
Both Drs. Lewalter and Cooper question the numerators used
or the maintenance of sinus rhythm from EURIDIS and
DONIS. We included those with recurrent AF on the basis of
able 2, row 5 “Recurrence at 12 mo, No. of patients.” These
umbers for the 1-year recurrence rate in EURIDIS (74.7%) are
onsistent with the effect reported in the DIONYSOS (Efficacy
nd Safety of Dronedarone versus Amiodarone for the Mainte-
ance of Sinus Rhythm in Patients with Atrial Fibrillation) trial
73.9%) (8). We agree with Dr. Cooper that greater clarity in the
ublished EURIDIS and ADONIS results would be desirable.
If one assumes the numerators and denominators for AF
ecurrence are as suggested by Dr. Cooper (EURIDIS: Placebo
56 of 201, Dronedarone 276 of 411; ADONIS: Placebo 151 of
08, Dronedarone 255 of 417), the overall conclusions are similar.
ssuming these results, dronedarone for the prevention of recur-
ent AF has an OR of 0.54 (95% confidence interval [CI]: 0.42 to
.71) compared with placebo. When incorporated into an indirect
eta-analysis, the estimated effect of amiodarone versus droneda-
one does not meaningfully change (OR: 0.23, 95% CI: 0.14 to
.38). Estimates using the totality of the evidence, including the
esults from the DIONYSOS trial, still indicate superiority of
miodarone over dronedarone (OR: 0.33, 95% CI: 0.14 to 0.52).
verall estimates using risk differences suggest that use of amio-
arone would be associated with 270 fewer AF recurrences/1,000
atients treated compared with dronedarone (95% CI: 0.35 to
0.19). The CI of this result has the same lower boundary as our
nitial analysis (OR: 0.36, 95% CI: 0.52 to 0.19).
We realize that the type and duration of AF are both predictive of
F recurrence (9,10). DAFNE, EURIDIS, and ADONIS excluded
atients with long-standing persistent AF. By contrast, SAFE-T
xcluded patients with paroxysmal AF, and GEFACA exclusively en-
olled patients with long-standing persistent/chronic AF. Although it
ould be desirable to adjust for these differences as a meta-regression
nalysis, this would require more detailed data than provided in the
ublished tables.
Recognizing the limitations inherent with indirect comparisons, we
urposefully incorporated the indirect estimates with head-to-head data
omparing dronedarone and amiodarone in the DIONYSOS trial.
he data from this clinical trial were consistent with our indirect preatment estimates. Our report conservatively summarizes the best
vailable evidence for the safety and efficacy of both of these important
reatment options. We wholeheartedly agree with Professor Lewalter
hat large pragmatic trials focused on definitive outcomes are crucial
or refining our understanding of these drugs.
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ardiac Rehabilitation for
atients With Ventricular
ssist Devices
n Offer to Improve
trong Collaborative Relationships
he review by Wilson et al. (1) outlines several important
rinciples in the outpatient management of patients with ventric-
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March 9, 2010:1051–4lar assist devices (VADs), including the provision of physical
xercise, nutrition, and routine self-care, as well as the coordina-
ion of effective communication among heart failure (HF) special-
sts, primary care providers, and first responders. The authors also
ecognize that adequate cardiac rehabilitation (CR) plays a central
ole in a patient’s recovery yet lamented that this is often difficult
o carry out for patients with VADs in a typical community setting,
ecause community rehab programs might be uncomfortable with
nrolling these patients.
As fellows of the American Association of Cardiovascular and
ulmonary Rehabilitation (AACVPR), we encourage profession-
ls who work in HF teams to reach out to AACVPR certified
rograms in their communities (2) to develop collaborative rela-
ionships to develop safe, effective CR environments. We also
elcome the opportunity to use the information from this article to
evelop educational programs for our members to help them serve
hese patients.
Cardiac rehabilitation is an excellent environment to reinforce
elf-management; provide emotional support; and increase exercise
olerance, functional capacity, and quality of life (3). Patients who
eceive VADs have been unable to perform much activity and have
ecome debilitated by the inherent disease process and prolonged
ed rest. This group would particularly benefit from CR to restore
hem to an acceptable physical function and provide education and
ounseling that would complement the education afforded by the
F team.
Although many insurance carriers do not currently cover mon-
tored (Phase 2) CR for patients with HF, efforts are ongoing to
ncourage such coverage. In the meantime, patients with HF are
overed by most insurance plans for Phase 2 CR if they have a
ualifying diagnosis (recent myocardial infarction, coronary artery
ypass surgery, percutaneous coronary intervention, heart valve
urgery, or heart transplantation). Alternatively, they can partici-
ate in a self-pay maintenance CR program (Phase 4, approximate
ost of $50 to $60/month), if deemed appropriate by their medical
are provider and by the CR team.
We agree with Wilson et al. (1) that a strong collaborative
elationship between HF and CR teams is essential to provide
ptimal care for patients with VADs and encourage cardiovascular
pecialists and professional associations devoted to improving care
or patients with HF to join with AACVPR to help make this
appen for our patients.
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1) and endorse their recommendations regarding physical therapy
nd rehabilitation for ventricular assist device (VAD) patients. As
he number of patients implanted with a VAD increases and as
hey transition back into their local communities, it is imperative
hat there is an increased awareness and knowledge of this unique
atient population. We strongly agree that cardiologists and heart
ailure specialists in particular need to reach out and develop a
ollaborative relationship with cardiac rehabilitation programs in
he development and implementation of an optimal environment
or the recovery of VAD patients. Although no large-scale trials
ave been performed to date, many VAD patients are debilitated
fter surgery and, like those individuals after cardiac transplanta-
ion, will benefit from an exercise rehabilitation program incorpo-
ating both muscular-strength and aerobic training (2). Additional
enefits of a strong multidisciplinary program include education
egarding nutrition and weight loss, lipid management, and
moking cessation as well as the positive reinforcement that comes
rom meeting others living with cardiovascular disease.
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